Swiss Biotech Stock News

SWX:WKBN
SWX:WKBNBanks

Assessing Walliser Kantonalbank (SWX:WKBN) Valuation After 2025 Results Show Lower Net Interest Income And Net Income

Earnings event and what changed Walliser Kantonalbank (SWX:WKBN) has released full year 2025 results, with net interest income of CHF 195.3 million and net income of CHF 85.87 million, both lower than the previous year. For you as an investor, the key question is how these earnings shifts affect the appeal of a regional Swiss bank that offers a broad mix of retail, lending, and wealth management services, all denominated in CHF. See our latest analysis for Walliser Kantonalbank. The share...
SWX:GALD
SWX:GALDPharmaceuticals

Galderma Group (SWX:GALD) Valuation Check After Record Results And Raised Nemluvio Outlook

Why Galderma’s latest results matter for shareholders Galderma Group (SWX:GALD) just reported record full year 2025 figures, with net sales of US$5,207 million and net income of US$613 million, and paired that with fresh 2026 guidance and product milestones. For investors, the combination of earnings, a completed share buyback and detailed growth expectations provides new information about how management is running the business and prioritising capital allocation. See our latest analysis for...
SWX:GALE
SWX:GALEHealthcare

Galenica (SWX:GALE) Valuation Check As Bichsel Consultation And Potential Job Cuts Progress

Why the Bichsel decision matters for Galenica shareholders Galenica (SWX:GALE) has launched a consultation process on a planned production closure at its Bichsel subsidiary, a move that could affect up to 170 jobs by the end of 2026. The company plans to support affected employees with financial assistance, career guidance, and potential alternative roles within the wider Galenica network. A final decision is expected after the consultation concludes in mid March 2026. See our latest analysis...
SWX:SDZ
SWX:SDZPharmaceuticals

Assessing Sandoz Group (SWX:SDZ) Valuation After Guidance, Dividend Increase And Ranluspec Approval

Sandoz Group (SWX:SDZ) just packed several developments into one week, combining full year 2025 results, fresh 2026 net sales guidance, a higher annual dividend, and new EU marketing authorization for its eye drug Ranluspec. See our latest analysis for Sandoz Group. The recent mix of higher 2025 sales and net income, fresh 2026 net sales guidance, a larger dividend and Ranluspec approval comes after a 1-day share price return of a 1.82% decline and a 7-day share price return of a 6.67%...
SWX:SGSN
SWX:SGSNProfessional Services

Assessing SGS (SWX:SGSN) Valuation After New Sustainable Mining Collaboration With Exterra

SGS collaboration with Exterra puts sustainable mining in focus SGS (SWX:SGSN) has entered a long-term collaboration with Exterra Technologies to test on-site regeneration of chemical inputs in mineral production, aiming to cut reagent costs and reduce environmental impact. See our latest analysis for SGS. While SGS shares have eased in the short term, with a 7 day share price return of 4.02% decline and a 30 day share price return of 2.37% decline, the 1 year total shareholder return of...
SWX:IDIA
SWX:IDIABiotechs

Idorsia (SWX:IDIA) Valuation Check After Recent Share Price Weakness And Pipeline Expectations

Idorsia (SWX:IDIA) is back on watch for investors after a recent stretch of weak share performance, with the stock showing negative moves over the past week, month and past 3 months. See our latest analysis for Idorsia. At a share price of CHF3.53, Idorsia’s recent share price returns show pressure in the short term, including a 1 day decline of 3.55% and a year to date drop of 13.05%. In contrast, the 1 year total shareholder return of just over 3x and the deeply negative 3 and 5 year total...
SWX:NEAG
SWX:NEAGElectric Utilities

A Look At Naturenergie Holding (SWX:NEAG) Valuation After Its 2025 Results And Dividend Confirmation

Earnings and dividend move naturenergie holding (SWX:NEAG) into focus Naturenergie holding (SWX:NEAG) has drawn fresh attention after reporting its 2025 results, showing higher net income and earnings per share despite lower sales and revenue, alongside confirming an annual dividend of CHF 0.90 per share. See our latest analysis for naturenergie holding. At a share price of CHF 32.80, naturenergie holding has seen a 1 day share price return of 1.55% and a 7 day share price return of 1.23%,...
SWX:HIAG
SWX:HIAGReal Estate

A Look At HIAG Immobilien Holding (SWX:HIAG) Valuation After Strong Full Year Earnings Results

Earnings jump and lower dividend put HIAG Immobilien Holding (SWX:HIAG) in focus HIAG Immobilien Holding (SWX:HIAG) is back on investors’ radar after releasing full year 2025 results, with higher revenue, net income and earnings per share, alongside a reduced annual dividend of CHF 0.06 per share. See our latest analysis for HIAG Immobilien Holding. The earnings release and smaller dividend cut have arrived after a strong run in the shares, with a 30 day share price return of 7.62% and a 90...
SWX:SPSN
SWX:SPSNReal Estate

Swiss Prime Site (SWX:SPSN) Valuation Check After CHF 350m Convertible Green Bond Issuance

Swiss Prime Site (SWX:SPSN) has drawn attention after announcing a CHF 350,000,000 private placement of senior unsecured convertible green bonds, a financing move that directly ties future equity dilution to bondholder conversion choices. See our latest analysis for Swiss Prime Site. Against this financing backdrop, Swiss Prime Site’s share price has risen to CHF143.2 with a 30 day share price return of 6.15% and a 90 day share price return of 22.18%. Its 1 year total shareholder return of...
SWX:SFSN
SWX:SFSNMachinery

Assessing SFS Group (SWX:SFSN) Valuation After Full Year Results And Dividend Announcement

Full year results and dividend decision set the tone for SFS Group stock SFS Group (SWX:SFSN) has been in focus after reporting full year 2025 results, with sales of CHF 3,045.4 million, net income of CHF 219 million, and a basic EPS of CHF 5.63. At the same time, the company confirmed an annual dividend of CHF 2.00 per share, with payment scheduled for April 30, 2026. This is a timeline many income focused investors will be watching closely. See our latest analysis for SFS Group. The latest...
SWX:CLTN
SWX:CLTNMedical Equipment

Coltene Holding (SWX:CLTN) Margin Improvement To 5.9% Challenges Cautious Profitability Narratives

COLTENE Holding (SWX:CLTN) has reported FY 2025 first half revenue of CHF118.1 million and basic EPS of CHF0.71, with the trailing twelve month figures sitting at CHF240.7 million of revenue and CHF2.39 of EPS. This gives investors an updated view on both top and bottom line performance. The company has seen revenue shift from CHF127.5 million with EPS of CHF1.74 in the first half of 2024 to CHF122.7 million and EPS of roughly CHF1.69 in the second half of 2024, before landing at the current...
SWX:PLAN
SWX:PLANReal Estate

Assessing Plazza (SWX:PLAN) Valuation After Its Higher Annual Dividend Announcement

Dividend announcement and key dates Plazza (SWX:PLAN) has announced an annual dividend of CHF 10.00 per share. The cash payment is scheduled for 9 April 2026, the ex-dividend date is 7 April, and the record date is 8 April. See our latest analysis for Plazza. Plazza's latest dividend move comes after a period of steadily positive momentum, with a 90 day share price return of 14.0% and a 1 year total shareholder return of 32.17% suggesting improving sentiment around both income and capital...
SWX:PSPN
SWX:PSPNReal Estate

Assessing PSP Swiss Property (SWX:PSPN) Valuation After Strong Earnings And Higher Dividend Announcement

PSP Swiss Property (SWX:PSPN) has released its full-year 2025 results, reporting sales of CHF 349.23 million and net income of CHF 408.47 million, along with an annual dividend of CHF 3.95 per share. See our latest analysis for PSP Swiss Property. The full-year earnings and higher dividend announcement come after a strong run in the shares, with an 18.27% 90-day share price return and a 29.31% 1-year total shareholder return, suggesting momentum has been building recently. If this update has...
SWX:ZURN
SWX:ZURNInsurance

Zurich Insurance Group (SWX:ZURN) Valuation Check After Record 2025 Profit And Higher Dividend Proposal

Why Zurich Insurance Group (SWX:ZURN) is back on investors’ radar Zurich Insurance Group (SWX:ZURN) has drawn fresh attention after reporting its highest-ever annual profit for 2025, supported by its U.S. Farmers Management Services business and a benign catastrophe year. The board has also proposed lifting the dividend to CHF 30 per share, a 7% increase, subject to shareholder approval, giving investors a fresh data point to reassess the stock. See our latest analysis for Zurich Insurance...
SWX:VZN
SWX:VZNCapital Markets

VZ Holding (SWX:VZN) Valuation Check After 2025 Results 2026 Guidance And Higher Dividend

VZ Holding (SWX:VZN) is back in focus after reporting full year 2025 results, issuing 2026 guidance on revenue and net profit, and announcing an annual dividend of CHF 2.95 per share. See our latest analysis for VZ Holding. The recent combination of 2025 earnings, 2026 guidance and a higher dividend seems to be feeding into sentiment. The 1-day share price return of 1.50% and 7-day share price return of 2.76% contrast with a year-to-date share price return decline of 1.46% and a 3-year total...
SWX:GALD
SWX:GALDPharmaceuticals

Galderma Group (SWX:GALD) Margin Jump Reinforces Bullish Profitability Narratives

Galderma Group (SWX:GALD) has just posted its FY 2025 results with first half revenue of US$2.5b and basic EPS of US$0.82, framing a year where trailing twelve month revenue reached about US$5.2b and EPS came in at US$2.60. The company has seen revenue move from US$2.2b and EPS of US$0.20 in the first half of 2024 to US$2.5b and EPS of US$0.82 in the first half of 2025, while trailing twelve month EPS stepped up from US$0.97 to US$2.60 over the same window. This sets up a story where...
SWX:ROG
SWX:ROGPharmaceuticals

Roche Obesity Drug Data Renews Focus On Valuation And Growth Prospects

Roche Holding (SWX:ROG) reported promising Phase II results for petrelintide, its investigational obesity drug. The trial showed clinically meaningful, sustained weight loss with a favorable tolerability profile. The company is advancing discussions and further development of petrelintide in chronic weight management. For investors following SWX:ROG, this update puts a fresh spotlight on Roche's efforts in obesity treatments, an area attracting intense attention across healthcare. The...
SWX:NEAG
SWX:NEAGElectric Utilities

How naturenergie’s Higher 2025 Profit, Bigger 2026 Capex and Lower EBIT Outlook Will Impact naturenergie holding (SWX:NEAG) Investors

Naturenergie holding AG recently reported its 2025 results, with EBIT of €214 million, higher annual profit, and gross investments of €174 million focused on system-relevant infrastructure, renewable generation, and customer-focused energy solutions, while also declaring an annual dividend of CHF 0.9000 per share payable on May 4, 2026. The company signalled that 2026 EBIT could fall to around €120 million due to weaker marketing prices and regulatory pressures, yet it still plans to lift...
SWX:SFSN
SWX:SFSNMachinery

SFS Group (SWX:SFSN) Margin Decline To 7.7% Tests Bulls Profitability Narrative

SFS Group (SWX:SFSN) has just posted its FY 2025 numbers, reporting first half revenue of CHF 1.6b and basic EPS of CHF 2.86. This provides an early indication of how the rest of the year might shape investor expectations. The company has reported revenue of CHF 1.56b in the first half of 2024, CHF 1.50b in the second half of 2024, and CHF 1.55b in the first half of 2025. Over the same periods, basic EPS was CHF 3.00, then CHF 3.21, and then CHF 2.86, giving a clear view of how the top line...
SWX:MOZN
SWX:MOZNSpecialty Retail

Mobilezone Holding (SWX:MOZN) Margin Compression To 1.6% Challenges Bullish Narratives

mobilezone holding ag (SWX:MOZN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 429.6 million and EPS of CHF 0.41 setting the tone for the year. The company has seen revenue move from CHF 476.1 million and EPS of CHF 0.44 in the first half of 2024 to CHF 525.3 million and EPS of CHF 0.0757 in the second half, before landing at the current run rate that feeds into trailing 12 month revenue of CHF 958.3 million and EPS of CHF 0.3618. With trailing net margins...
SWX:SIGN
SWX:SIGNPackaging

SIG Group (SWX:SIGN) Is Down 5.6% After Swinging To A 2025 Net Loss - What's Changed

SIG Group AG has released its full-year 2025 results, reporting sales of €3,248.7 million versus €3,328.5 million a year earlier and moving from net income of €194.5 million to a net loss of €87 million. The swing from earnings per share of €0.51 to a basic and diluted loss per share of €0.23 highlights a sharp deterioration in profitability that may prompt investors to reassess the company’s earnings outlook. We’ll now examine how this move from profit to net loss in 2025 could reshape SIG...
SWX:CICN
SWX:CICNElectronic

Cicor Technologies H1 EPS Drop Tests Bullish Earnings Growth Narrative

Cicor Technologies (SWX:CICN) has reported H1 2025 revenue of CHF 280.7 million and basic EPS of CHF 1.93, setting the stage after a year in which earnings grew 49.7% and net profit margin moved from 3.8% to 4.5%. Over the past three reported halves, revenue has moved from CHF 231.3 million in H1 2024 to CHF 249.5 million in H2 2024 and now CHF 280.7 million in H1 2025, while basic EPS shifted from CHF 2.69 to CHF 3.52 and then CHF 1.93, with margins now doing more of the heavy lifting in the...
SWX:COTN
SWX:COTNElectronic

Comet Holding (SWX:COTN) TTM Margin Improvement To 8.1% Tests High Multiple Narrative

Comet Holding (SWX:COTN) has reported its FY 2025 first half results with revenue of CHF 227.2 million and EPS of CHF 1.01, while the trailing twelve months show revenue of CHF 483.2 million and EPS of CHF 5.02 based on the data provided. The company has seen revenue move from CHF 189.3 million and EPS of CHF 0.52 in the first half of 2024 to CHF 256.0 million and EPS of CHF 4.02 in the second half of 2024, setting up FY 2025 against a backdrop of improving net margins and profitability that...
SWX:ALSN
SWX:ALSNElectronic

Assessing ALSO Holding (SWX:ALSN) Valuation After Announcing A €120 Million Share Buyback Program

ALSO Holding (SWX:ALSN) has announced a new €120 million share buyback program, targeting up to 9.74% of its share capital for treasury use, acquisitions, liquidity, and management incentives. See our latest analysis for ALSO Holding. The buyback news comes after a weak patch for the shares, with a 30 day share price return showing a decline of 16.53% and a year to date share price return showing a decline of 23.16%. The 1 year total shareholder return shows a decline of 37.67%, which...